紫杉醇类辅助化疗对HER-2阳性乳腺癌患者生存率影响的研究.docVIP

紫杉醇类辅助化疗对HER-2阳性乳腺癌患者生存率影响的研究 436岭南现代临床外科2006年12月第6卷第6期LingnanModernClinicsinSurgery,— Eee.2006,— Vo1.6No.6 紫杉醇类辅助化疗对HER一2阳性乳腺癌患者 生存率影响的研究 龚畅李少华贾卫娟宋尔卫苏逢锡 中山大学附属第二医院乳腺肿瘤中心(51012O) 【摘要】目的探讨含紫杉醇类辅助化疗方案对HER一2(表皮生长因子受体2)阳性乳腺癌患者生存率的影 响.方法选取2001年5月至2004年10月我院乳腺肿瘤中心HER一2阳性的早期乳腺患者191名,随访至疾病 进展,分析她们的临床特征(年龄,手术方式)和病理学特征(激素受体状态,HER一2状态),化疗方案与生存率的关 系.结果平均随访29.8个月,总复发转移率12.57%(24/191),乎均疾病进展时间27.17个月.其中用只含蒽环 类辅助化疗者无病存活率80/96=83.33%,含紫杉醇类辅助化疗者无病存活率97.10%(67/69)(x=35.67,Plt; 0.001).其中ER,PR均阴性者99人,用只含葸环类化疗复发转移24.07%(13/54),含紫杉醇类化疗复发转移 2.86%(1/35)(X=101.1O,Plt;O.0001).结论含紫杉醇类药物进行术后辅助化疗能增加HER一2阳性乳腺癌患者无 病生存获益,尤其是对ER,PR均阴性且HER-2阳性者. 【关键词】乳腺癌;化疗;表皮生长因子受体2 中图分类号:R730.53:R737.9文献标识码:A文章编号:1009—976X(2006l06—0436—02 Studyontheeffectsofsurvivalratebyusingadjuvantchemotherapyincluding paclitaxelonpatientswithHER-2positivebreastcancer GONGChang,LIShaohua,JIAWe~uan,SONGErwei,SUFengxi BreastTumorCentre,TheSecondAffiliatedHosphal,SunYat—senUniversity,Guangzhou, 510120 【Abstract】ObjectiveToinvestigatetheeffectsofsurvivalrateintheuseofadjuvant chemotherapycontainingpaclitaxelonpatientswithbreastcancerofHER一2positive.Methods FromMay2001toOctober2004,191caseswithHER一2positivebreastcancer,werefollowed—up untildiseaseprogress,andtherelationshipbetweenclinicalfeature,pathologicaltype, chemotherapeuticprojectandsurvivalratewereanalyzedretrospectively.ResultsThemean follow—upis29.8months.Thetotalrecurrentmetastaticratewas12.57%(24/191),Themean progressivetimeofdiseasewas27.17months.Forthepatientsreceivedchemotherapyonlyusing containedanthracyclineorpaclitaxe1.thedisease—freesurvivalis83_3%and97.10%respectively. TheERandPRwerenegativein99cases,andamongthem,inthepatientsreceived chemotherapyonlyusinganthracyclineorpaclitaxel,therecurrentmetastaticratewere24.07% (13/54)and2.86%(1/35)respectively.(X2=101.10,Plt;O.0001).ConclusionsAdjuvant chemotherapycontainingpaclitaxelcanimprovethedisease-freesurvivalofbreastcancerwith HER-2positive,especiallyforthepatientswithERandPRnegative. 【KeyWords】Breastcancer;Chemothe